Committed to the development of gene therapy for patients with rare and severe genetic diseases
“Castle Creek Biosciences” official website
According to foreign media Reported that recently, the gene therapy company “ Castle Creek Biosciences ” has received $ 75 million in equity plus debt financing < / strong>. In this round of financing, Paragon Biosciences led a $ 55 million equity investment, with Fidelity Management & Research Company and Valor Equity Partners participating; Horizon Technology Finance Corporation provided a $ 20 million venture loan.
“Castle Creek Biosciences” is a company that develops and commercializes gene therapies for patients with rare and severe genetic diseases.
Castle Creek Biosciences is using its proprietary technology platform and infrastructure to develop personalized gene therapies to address rare diseases that have yet to be resolved. Fibroblasts are the foundation of “Castle Creek Biosciences” personalized gene therapy platforms, as they are the most common cells in the skin and connective tissue and are responsible for the synthesis Extracellular matrix proteins, including collagen, provide structure and support to cells.
「Castle Creek Biosc”Iences” is also a invested company of Paragon Biosciences. Paragon Biosciences focuses on biopharmaceuticals, uses AI technology to develop life science related products, and develops advanced cell and gene therapy.
“Castle Creek Biosciences” official website
“Castle Creek Biosciences” gene therapy candidate FCX-007 (NCT04213261) can be used to treat recessive dystrophic bullous epidermolysis (RDEB), a serious and rapidly debilitating person Bullous Epidermolysis (EB). “Castle Creek Biosciences” plans to submit research protocols for the drug to the BLA (Biological Product Licensing Application) in 2021.
From the clinical results of the FCX-007 half-term clinical trial, it can be seen that RDEB patients have a positive trend in wound healing, and the safety of recovery is high. “Castle Creek Biosciences” presented the latest data from the clinical trial at the first World Bullous Epidermolysis Conference in London in January 2020. The company applied FCX-007 to 10 unhealed chronic wounds, 8 of which achieved complete wound closure 12 weeks after dosing. FCX-007 was still well tolerated by the patient after 52 weeks of dosing.
Castle Creek Biosciences is also advancing clinical research to evaluate diacerein topical cream CCP-020 for the treatment of simple bullous epidermolysis (EBS) and other forms of EB. In addition, “Castle Creek Biosciences” is developing FCX-013, a gene therapy for the treatment of moderate to severe localized scleroderma.
“Castle Creek Biosciences” plans to use the funds to advance and expand its gene therapy product line to FCLed by Phase III clinical development of X-007, this funding will also be used to expand its cGMP (Dynamic Drug Manufacturing Management) infrastructure in the Philadelphia area and expand the scope of its gene therapy platform.